Solriamfetol Significantly Reduces ADHD Symptoms in Axsome’s Phase 3 Trial

Published Date: 11 Apr 2025

Axsome’s phase 3 trial shows solriamfetol significantly improves ADHD symptoms, with a 45% mean reduction in AISRS scores and onset as early as week 1.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

AI model combines clinical and magnetic resonance data to improve prediction of breast cancer recurrence

2.

'It's rare and it's scary.' Dark spot on your fingernail could mean cancer

3.

24 months after radical prostateectomy, no PSA recurrence was observed when using apalutamide plus ADT.

4.

Modified personalized cancer vaccine generates powerful immune response

5.

Spouses of Cancer Patients May Be at Increased Risk of Suicide


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot